Provention Bio, Inc. (PRVB) shares rallied 25.7% in the last trading session to close at $6.22. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 2.7% gain over the past four weeks. The stock rallied driven by optimism over the company's collaboration and co-promotion agreement with Sanofi for the commercialization of lead investigational drug candidate teplizumab. This company is expected to post quarterly loss of $0.46 per share in its upcoming report, which represents a year-over-year change of -7%. Revenues are expected to be $0.88 million, up 28.7% from the year-ago quarter. While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.